Adverse effects: Death ‐ long termOccurrences of death · patients with schizophrenia
ORAL FLUPHENAZINE showed no clear difference in adverse effects: Death ‐ long termOccurrences of death compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (rigidity) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (akathisia) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes adverse effects: Extrapyramidal effects ‐ akathisia ‐ short term (up… compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Adverse effect: extrapyramidal symptoms ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Extrapyramidal effects ‐ concomitant anticholinergic medication ‐ short term (up to 12 weeks) Participants requiring concomitant anticholinergic medication · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes adverse effects: Extrapyramidal effects ‐ concomitant… compared with AMISULPRIDE (very low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE DECANOATE changes extrapyramidal adverse effects ‐ general compared with ORAL NEUROLEPTICS (very low certainty).
1 finding from 1 review
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short term Numbers requiring anticholinergic medication · patients with schizophrenia or related psychoses
It is very uncertain whether FLUPENTHIXOL DECANOATE changes adverse effects: general ‐ movement disorders ‐ requiring… compared with ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review